本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：920925 证券简称：锦好医疗 公告编号：2026-008 惠州市锦好医疗科技股份有限公司 第三届董事会第二十次会议决议公告 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 2 月 2 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2026 年 1 月 30 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 二、议案审议情况 （一）审议通过《关于向 2025 年限制性股票激励计划激励对象授予预留权益的 议案》 1.议案内容： 具体内容请见公司同日在北京证券交易所信息披露平台(www.bse.cn)披露的 《2025 年限制性股票激励计划预留权益授予公告》（公告编号：2026-009）。 （二）会议出席情况 会议应 ...

Core Viewpoint - The company, Jinhao Medical, is expected to see significant profit growth in 2025, driven by increased demand in the US OTC hearing aid market and strategic partnerships [1] Financial Performance - As of January 27, 2026, Jinhao Medical's stock closed at 23.75 yuan, down 3.46% from the previous trading day, with a total market capitalization of 2.338 billion yuan [1] - The company anticipates a net profit attributable to shareholders of 15 million to 16 million yuan for 2025, representing a growth of 150.98% to 167.72% compared to the previous year's profit of 597.65 million yuan [1] Business Strategy - The growth in performance is attributed to the rising demand in the US OTC hearing aid market, enhanced collaboration with brand partners, and the promotion of its own brand through a full-channel operation [1] - The acquisition of Intricon's hearing health business is expected to contribute approximately 20 million yuan in hearing aid chip sales revenue, an increase of about 16.5 million yuan year-on-year [1]

证券代码：920925 证券简称：锦好医疗 公告编号：2026-007 惠州市锦好医疗科技股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 √年度实现盈利，且净利润与上年同期相比上升 50%以上 注：因实施 2025 年限制性股票激励计划，2025 年计提股份支付金额约为 319 万元。 二、本期业绩重大变化的主要原因 2025 年公司归属于上市公司股东净利润预计同比增长，主要原因如下： 1、美国 OTC（非处方）市场需求持续增长，全渠道运营驱动公司助听器主 业增长。 (二)业绩预告情况 2024 年 9 月收购 Intricon 听力健康业务后，公司快速消化吸收其助听器 DSP 芯片 ...

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Group 1 - The stock price of Jinhai Medical (920925) closed at 24.79 yuan on January 19, 2026, with a slight increase of 0.08% and a turnover rate of 2.99% [1] - The trading volume was 16,500 shares, with a total transaction amount of 40.9653 million yuan [1] - On January 19, the main funds experienced a net outflow of 2.5742 million yuan, accounting for 6.28% of the total transaction amount, while retail investors had a net inflow of 115,500 yuan, representing 0.28% of the total [1][3] Group 2 - Jinhai Medical announced the internal public notice of the list of incentive objects for the 2025 restricted stock incentive plan from January 6 to January 16, 2026, with no objections from employees during the public notice period [1] - The independent directors confirmed that the incentive objects meet the relevant legal regulations and the conditions specified in the draft of the 2025 restricted stock incentive plan, and they are qualified for the position [1] - The incentive objects include senior management and core employees of the company and its subsidiaries, excluding independent directors and foreign employees [1]

《独立董事专门会议关于2025年限制性股票激励计划预留权益授予激励对象名单的审查意见及公 示情况说明的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 截至2026年1月19日收盘，锦好医疗（920925）报收于24.79元，较前一交易日上涨0.08%，最新总市值 为24.41亿元。该股当日开盘24.92元，最高24.92元，最低24.66元，成交额达4096.53万元，换手率为 2.99%。 公司近日发布公告称，惠州市锦好医疗科技股份有限公司于2026年1月6日至1月16日对2025年限制性股 票激励计划预留权益授予的激励对象名单进行了内部公示，公示期间员工无异议。公司独立董事专门会 议审查认为，激励对象符合相关法律法规及《2025年限制性股票激励计划（草案）》规定的条件，具备 任职资格，未发现不得成为激励对象的情形。激励对象为公司及子公司的高级管理人员和核心员工，不 包括独立董事及外籍员工。独立董事认为本次激励对象的确定合法、有效。 ...

惠州市锦好医疗科技股份有限公司 独立董事专门会议关于 2025 年限制性股票激励计划 预留权益授予激励对象名单的审查意见及公示情况说明的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开 第三届董事会第十九次会议，审议通过了《关于公司 2025 年限制性股票激励计划授予 的 激 励对 象名 单的议 案 》， 并于 2026 年 1 月 6 日在 北京 证 券交 易所 官 网 （http://www.bse.cn）上披露了《2025 年限制性股票激励计划预留权益授予的激励对象 名单》（公告编号 2026-003）。公司独立董事专门会议结合公示情况对激励对象进行了 审查，相关公示情况及审查情况如下： 证券代码：920925 证券简称：锦好医疗 公告编号：2026-006 2.列入公司《激励对象名单》的人员具备《中华人民共和国公司法》《公司章程》 等法律、法规和规范性文件规定的任职资格，不存在《上市公司股权激励管理办法 ...

Core Viewpoint - The company JinHao Medical has reported an increase in stock price and provided updates on the use of idle funds for purchasing financial products, indicating a strategic approach to asset management [1]. Group 1: Stock Performance - As of January 13, 2026, JinHao Medical's stock closed at 26.66 yuan, up 1.21% from the previous trading day [1]. - The stock opened at 26.6 yuan, reached a high of 27.5 yuan, and a low of 26.2 yuan, with a trading volume of 2.4 billion yuan and a turnover rate of 16.12% [1]. Group 2: Financial Product Investment - The company announced the use of up to 100 million yuan of idle self-owned funds to purchase low-risk, high-liquidity bank financial products, approved by the board on October 27, 2025 [1]. - As of January 13, 2026, the remaining balance of the purchased financial products was 60.2 million yuan, representing 16.92% of the company's audited net assets as of the end of 2024 [1]. - The company has added a purchase of 10 million yuan in structured deposits from the Bank of China, with a term of 119 days and an expected annual yield of 0.6% or 1.9%, funded by self-owned capital [1].

关于使用部分闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 惠州市锦好医疗科技股份有限公司 证券代码：920925 证券简称：锦好医疗 公告编号：2026-005 （一） 本次委托理财产品的基本情况 （一）购买理财产品的审议情况 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第三届董事会第十七次会议审议通过《关于使用部分闲置自有资金购买银 行理财产品的议案》。为提高公司资金使用效率，在确保资金安全、不影响公司 正常经营的前提下，公司合理利用部分暂时闲置自有资金购买银行理财产品。使 用额度不超过人民币 10,000 万元的自有闲置资金购买安全性高、流动性好、风 险较低的理财产品，在此额度内可以循环滚动使用。具体内容详见公司 2025 年 10 月 29 日在北京证券交易所（www.bse.cn）披露的《关于使用部分闲置自有资 金购买银行理财产品的公告》（公告编号：2025-122）。 （二）购买理财产品 ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]